Software engineers straight out of college often make six-figure salaries, not counting equity compensation.Technologyread more
Representatives from the Chinese side say they think it likely that Chinese President Xi Jinping will attend the G-20 meeting later this month. But in order to reach a trade...China Economyread more
Wall Street, though, is clamoring for a rate cut, with an 85% chance of a move in July and a 61% probability of three reductions by year's end.The Fedread more
A company spokesperson said the outage was the result of a "an internal technology issue" and was not security related.Retailread more
Using MIT's living wage calculator, CNBC Make It mapped out the minimum amount a single parent must earn to meet their basic needs without relying on outside help in every...Earnread more
In the survey, 66% of Democratic primary voters say they'd be enthusiastic or comfortable about Biden as their nominee to take on President Trump in the 2020 election. Just...Politicsread more
The flattening of the yield curve is exuding a bad omen for the stock market if history is any guide.Marketsread more
Stratolaunch, the world's largest airplane, which flew once, is up for sale, sources familiar told CNBC.Investing in Spaceread more
Transparency is key… or is it? With the first-ever non-transparent, actively managed exchange-traded fund receiving approval from the SEC, "ETF Edge" goes straight to the...ETF Edgeread more
Mired in a crisis over its best-selling 737 Max plane, Boeing could hand the spotlight over to its rival Airbus at the Paris Air Show.Airlinesread more
A new update to the Apple Watch called watchOS 6 will notify you if the environment you're in is too loud and could damage your hearing.Technologyread more
Celgene raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares.
Revlimid sales soared about 18 percent to $1.70 billion, above Wall Street's consensus estimate of about $1.66 billion.
With Revlimid sales driven by new patient market share gains and longer duration of use, Celgene raised the full-year sales forecast for the medicine to $6.8 billion from $6.7 billion.
Celgene suffered a setback this week in efforts to expand Revlimid's uses when the drug failed to extend survival as a maintenance therapy for a type of lymphoma after patients had responded to prior treatment.
But the company said it would be wrong to draw conclusions from that data regarding three other late-stage Revlimid lymphoma trials in different patient populations and treatment settings, and expressed confidence in its potential there.
"Lymphoma will be a major growth driver in 2020 and beyond," Michael Pehl, head of hematology and oncology, told analysts on a conference call.
Celgene's new psoriasis drug Otezla, which is also being tested for atopic dermatitis and ulcerative colitis, posted sales of $274 million in the quarter.
"Otezla is on its way to hitting the $1 billion revenue milestone this year," said Chief Operating Officer Jackie Fouse, adding that it would become the company's fourth blockbuster product.
The company also highlighted the potential of its experimental Crohn's disease drug GED-301 as a key future growth driver, with important data expected this quarter.
"If that data looks good, we think that could be a big catalyst for the stock," said RBC Capital Markets analyst Michael Yee, who called it a potential $2 billion a year product.
Celgene raised its adjusted earnings forecast for 2016 to a range of $5.70 to $5.75 per share, from $5.60 to $5.70.
Excluding items, Celgene earned $1.44 per share in the quarter, topping analysts' average expectations by 6 cents, according to Thomson Reuters I/B/E/S.
"They continue to execute and outperform," Yee said, calling Celgene a standout among large biotechs.
Total revenue rose about 21 percent to $2.75 billion in the quarter, roughly in line with estimates.
Net income rose to $598.2 million, or 75 cents per share, from $356.2 million, or 43 cents per share, a year earlier.
Celgene shares rose 2.2 percent to $110.44 on Nasdaq after rising as high as $111.70.